Proton Bio is mainly engaged in gene and cell therapy CDMO service provider, focusing on the field of gene and cell therapy.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 19, 2022 | Series B | ¥520M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
China Merchants Securities | — | Series B |
Huatai Health Fund | — | Series B |